AmpliPhi Biosciences Corp (47) | Uncategorized (10)

Recent Contracts

Description of the Companys securities registered under Section 12 of the Exchange Act (Filed With SEC on March 17, 2022)
Description of the Companys securities registered under Section 12 of the Exchange Act (Filed With SEC on March 18, 2021)
Letter Agreement, dated as of March 10, 2020, by and between Armata Pharmaceuticals, Inc. and the Cystic Fibrosis Foundation (Filed With SEC on May 14, 2020)
Description of the Companys securities registered under Section 12 of the Exchange Act (Filed With SEC on March 19, 2020)
Form of Director Appointment Letter (Filed With SEC on May 10, 2019)
Engagement letter agreement, dated December 13, 2017, as amended on December 17, 2018, by and between the Company and Ladenburg Thalmann & Co. Inc (Filed With SEC on March 25, 2019)
Form of Company Support Agreement, dated January 3, 2019, by and between C3J Therapeutics and each of the parties named in each agreement therein (Filed With SEC on January 4, 2019)
Form of C3J Therapeutics Support Agreement, dated January 3, 2019, by and between the Company and each of the parties named in each agreement therein (Filed With SEC on January 4, 2019)
Form of Company Lock-Up Agreement, dated January 3, 2019, by each of the parties named in each agreement therein (Filed With SEC on January 4, 2019)
Form of C3J Lock-Up Agreement, dated January 3, 2019, by each of the parties named in each agreement therein (Filed With SEC on January 4, 2019)